- Migraine - Causes, Symptoms and Treatment By : Juliet Cohen
Migraine is a neurological disease of which the most common symptom is an intense and disabling episodic headache. Migraine headaches are usually characterized by severe pain on one or both sides of the head. - SCHWARZ PHARMA Highlights The Results Of 13 Lacosamide Data Presentations At North American Regional By : Epilepsy News
As part of its ongoing scientific research program for lacosamide, SCHWARZ PHARMA presented an overview of comprehensive pre-clinical and clinical data at the North American Regional Epilepsy Congress, including a positive Phase III trial - SCHWARZ PHARMA Unveils Positive Phase III Data On Lacosamide At North American Regional Epilepsy Con By : Endocrinology News
For the first time at the North American Regional Epilepsy Congress, SCHWARZ PHARMA presented results from one of its Phase III trials, which investigated the efficacy and safety of oral lacosamide as adjunctive therapy in adults with uncontrolled partial seizures. - Phase II Data Shows Ovation's Novel Compound Clobazam To Be Well Tolerated In Patients With Catastro By : Epilepsy News
Results from the first study in the United States designed to evaluate the safety and efficacy of clobazam as adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS), one of the most severe forms of childhood epilepsy, demonstrated - Breakthrough Research Presented At American Epilepsy Society (AES) Meeting By : Epilepsy News
Close to 4,000 physicians, researchers, nurses and other healthcare professionals from around the world have gathered in San Diego starting today through Tuesday, December 5th - Teva Announces Tentative Approval Of Sumatriptan Succinate Tablets By : Migraine News
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Sumatriptan Succinate Tablets, 25 mg, 50 mg and 100 mg. - 5,000 Walkers Expected At First-Ever National Walk For Epilepsy By : Epilepsy News
The Epilepsy Foundation announced today the site of the first-ever National Walk for Epilepsy. On March 31, 2007 thousands of people will take a 5K trek from Constitution Avenue to Jefferson Drive on the National Mall in Washington, D.C., to raise awareness and money for research to ensure that not another moment is lost to seizures. - Eisai Recieves Positive Opinion For Inovelon(R) Marketing Authorization From European Committee By : Epilepsy News
Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) announced today that on November 16 (U.K. time) the company's UK subsidiary Eisai Ltd. (Headquarters: London, Managing Director: Paul Hooper) received a positive opinion that recommends a marketing approval of the anti-epileptic agent Inovelon(R) (rufinamide) for adjunctive therapy in Lennox-Gastaut Syndrome (LGS) - Herbal Medication Relieves Painful Migraine Headaches By : Migraine News
Raghu Bajwa MD, Chairwoman of Guruji Herbal, Inc. announced the availability of Migrowin(C)(R)(TM) at the Complementary and Natural Healthcare CAM EXPO. - Gene Therapy Inhibits Epilepsy In Animals By : Epilepsy News
For the first time, researchers have inhibited the development of epilepsy after a brain insult in animals. By using gene therapy to modify signaling pathways in the brain, neurology researchers found that they could significantly reduce the development of epileptic seizures in rats. - New Guidelines to Treat Behavior Problems Following Traumatic Brain Injury Published in Journal By : Health News
Important new, evidence-based guidelines for the pharmacologic treatment of behavior problems associated with traumatic brain injury are published in the October issue (Volume 23, Number 10) of Journal of Neurotrauma, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). These guidelines are available free online at www.liebertpub.com/neu. - Elekta Selected to Deliver Four Advanced Radiation Therapy Systems to Ireland By : Health News
Elekta (STO:EKTA), a world leader in advanced radiation therapy, comprehensive cancer management and non-invasive treatment of brain disorders, today announced the award of business from St Luke’s Hospital in Dublin, Ireland. The full project, with a total value of over 10 MEUR includes the installation of four Elekta Synergy®, Elekta’s highly advanced medical linear accelerators incorporating intensity modulated and image guided radiation therapy (IMRT and IGRT). - Commonplace Sugar Compound Silences Seizures By : Epilepsy News
Though in clinical use for decades, a small, sweet-tasting compound is revealing a startling new face as a potential cure for epilepsy. - Playing Space Invaders Using Only The Signals From The Brain To Make Movements By : Epilepsy News
A St. Louis-area teenage boy and a computer game have gone hands-off, thanks to a unique experiment conducted by a team of neurosurgeons, neurologists, and engineers at Washington University in St. Louis. - COPAXONE® Showed Sustained Benefit on Slowing Brain Tissue Damage in Multiple Sclerosis Patients By : Health News
Data presented last week at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Madrid, Spain, showed that COPAXONE® (glatiramer acetate injection) may slow the neurodegenerative tissue damage that is a key aspect of multiple sclerosis (MS) disease pathology. - FDA Approves New Epilepsy Indication For Lamictal® By : Epilepsy News
The Food and Drug Administration today approved a new use of the anti-seizure medicine Lamictal® (lamotrigine) Tablets for the treatment of one of the most serious forms of epilepsy -- Primary Generalized Tonic-Clonic (PGTC) seizures, also known as “grand mal” seizures. With this new indication, Lamictal can now be used as add-on therapy to treat PGTC seizures in children aged 2 and older as well as adults. - FDA Approves New Epilepsy Indication For Lamictal(R) By : Epilepsy News
The Food and Drug Administration today approved a new use of the anti-seizure medicine Lamictal(R) (lamotrigine) Tablets for the treatment of one of the most serious forms of epilepsy -- Primary Generalized Tonic-Clonic (PGTC) seizures, also known as "grand mal" seizures. With this new indication, Lamictal can now be used as add-on therapy to treat PGTC seizures in children aged 2 and older as well as adults. - Licensing Arrangement Reached For Antiepileptic Drug Developed At Hebrew University By : Epilepsy News
A worldwide licensing arrangement for development, production and marketing of an antiepileptic drug created at the Hebrew University of Jerusalem has been signed by Shire Pharmaceuticals with Yissum, the Hebrew University's technology transfer company. Shire is a multinational firm with operations in North America, Europe and the Far East. - Elekta to Deliver Leksell Gamma Knife(R) Perfexion(TM) to University of Virginia By : Health News
The University of Virginia Health System (U.Va.) will become one of the first centers in the world to install the new Leksell Gamma Knife(R) Perfexion(TM), the most advanced system ever for non-invasive radiosurgery for brain disorders. - Multiple Sclerosis Damage Also Found In "Normal" Brain Tissue By : Multiple Sclerosis News
The effects of multiple sclerosis (MS) extend beyond visibly affected areas into large portions of the brain that outwardly appear normal, according to a study appearing in the September issue of Radiology - BrainStorm Cell Therapeutics Receives Upgrade by Respected Research Firm By : Health News
BrainStorm Cell Therapeutics (OTC BB: BCLI) is pleased to announce a well-respected firm, TRI-STATE Capital (TSC), has upgraded their equity rating on BrainStorm with a twelve month target price of $1.20. TSC is noted for their work with, account executives, analysts, portfolio managers, institutions, venture capital investors, individual investors and the media. To view the entire independent research report, please click on the attached URL: http://www.otclive.com - Epilepsy Action Seizes The Chance To Open Research Access By : Epilepsy News
Epilepsy Action announced today that it will begin making articles from its journal Seizure available free of charge on the worldwide web 12 months after publication. - Researchers Discover Brain Abnormality In Kids With Autism By : Autism News
Children with autism have altered brain anatomy thought to be due to abnormal brain development, according to a study published in the August 22, 2006, issue of Neurology, the scientific journal of the American Academy of Neurology. - FDA Approves Keppra(R) As Adjunctive Therapy In The Treatment Of Myoclonic Seizures By : Epilepsy News
Today UCB announced that the U.S. Food & Drug Administration (FDA) has approved the use of Keppra(R) (levetiracetam) as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy (JME). Keppra(R) is widely prescribed as an add-on therapy in the treatment of partial onset seizures in adults and children four years of age and older with epilepsy. - Study Provides Evidence That Autism Affects Functioning Of Entire Brain By : Autism News
A recent study provides evidence that autism affects the functioning of virtually the entire brain, and is not limited to the brain areas involved with social interactions, communication behaviors, and reasoning abilities, as had been previously thought. - From Chimp To Human, Brain Gene Shows Dramatic Difference By : Genetics News
One of the fastest-evolving pieces of DNA in the human genome is a gene linked to brain development, according to findings by an international team of researchers published in the Aug. 17 issue of the journal Nature. - Seizure Treatment Could Be Improved By Boosting Key Protein In Brain, Stanford Study Finds By : Epilepsy News
A naturally occurring protein in our brains could be the basis for a more promising epilepsy treatment - without the nasty side effects caused by many of the current medications. - Gene Related To Brain Development And Function Plays Causal Role In Schizophrenia Study Finds By : Schizophrenia News
According to a new study conducted by researchers at Mount Sinai School of Medicine, variations of a gene related to brain development and function--OLIG2--may play a causal role in the development of schizophrenia, a hereditary psychiatric disorder with no known biological cause. The study is published in the August 15 printed issue of Proceedings of National Academy of Sciences. - Epilepsy Drug Poses High Risk For Fetal Death And Birth Defects By : Medical News
The epilepsy drug valproate poses a higher risk for fetal death and birth defects than other commonly used epilepsy drugs, according to a study published in the August, 2006, issue of Neurology, the scientific journal of the American Academy of Neurology. - Pfizer Japan Obtains Manufacturing Approval Of Gabapentin For Antiepileptic By : Medical News
Pfizer Japan Inc. has obtained manufacturing approval of Gabapentin on July 26. Gabapentin can be taken in conjunction with other drugs. Since it does not induce drug-metabolizing enzymes, it has proven to be safely taken with other drugs. - New Data Demonstrate Effectiveness Of LAMICTAL® (lamotrigine) As Adjunctive Therapy For PGTC Seizure By : Medical News
Data published in today's issue of Pediatrics show that lamotrigine (LAMICTAL) is an effective add-on therapy for the treatment of Primary Generalized Tonic-Clonic (PGTC) seizures in a subgroup of children and adolescents. - Tiny Inhaled Particles Take Easy Route From Nose To Brain By : Medical News
In a continuing effort to find out if the tiniest airborne particles pose a health risk, University of Rochester Medical Center scientists showed that when rats breathe in nano-sized materials they follow a rapid and efficient pathway from the nasal cavity to several regions of the brain, according to a study in the August issue of Environmental Health Perspectives. - FDA Approves Keppra(R) Intravenous Formulation By : Medical News
Today UCB announced that the U.S. Food and Drug Administration (FDA) has approved Keppra(R) (levetiracetam) injection 500mg/5mL (100mg/mL) for use as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy. Keppra(R) injection is an alternative for patients when oral administration is temporarily not feasible; it must be diluted prior to use and administered as a 15-minute intravenous infusion.
|
